Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3939357 | 0.92 | HTT (0.33) | HTT | |
| SCHEMBL4557038 | 0.89 | — | — | |
| SCHEMBL4558705 | 0.88 | — | — | |
| SCHEMBL4558997 | 0.88 | — | — | |
| SCHEMBL4558742 | 0.87 | — | — | |
| SCHEMBL4558296 | 0.86 | — | — | |
| SCHEMBL3940382 | 0.84 | HTT (0.36) | HTT | |
| SCHEMBL3935443 | 0.83 | HTT (0.40) | HTT | |
| SCHEMBL3945491 | 0.82 | HTT (0.34) | HTT | |
| SCHEMBL27616373 | 0.82 | HTT (0.34) | HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1661897-B1 | PYRROLOPYRIMIDINONE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-7557113-B2 | Substituted pyrrolo[3,2-d]pyrimidine derivatives | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-7528140-B2 | Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors | TEIJIN LIMITED (JP) | 2009-05-05 | — | — | US | disclosed |
| US-20060160831-A1 | Pyrrolopyrimidinone derivatives | TEIJIN PHARMA LIMITED (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1661896-A1 | PYRROLOPYRIMIDINETHIONE DERIVATIVE | Teijin Pharma Limited (JP) | 2006-05-31 | — | — | EP | disclosed |
| EP-1661897-A1 | PYRROLOPYRIMIDINONE DERIVATIVE | Teijin Pharma Limited (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-20050277773-A1 | Pyrrolopyrimidine derivatives | TEIJIN LIMITED (JP) | 2005-12-15 | — | — | US | disclosed |
| US-20050153992-A1 | Pyrrolopyrimidine thion derivatives | TEIJIN PHARMA LIMITED (JP) | 2005-07-14 | — | — | US | disclosed |
| EP-1477489-A1 | PYRROLOPYRIMIDINE DERIVATIVES | TEIJIN LIMITED (JP) | 2004-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153992-A1 | Pyrrolopyrimidine thion derivatives | GSK3B, GSK3A, GSKIP | HTT 1516/4885 |
| US-20050277773-A1 | Pyrrolopyrimidine derivatives | GSK3B, GSK3A, GSKIP | HTT 3815/4885 |
| US-20060160831-A1 | Pyrrolopyrimidinone derivatives | GSK3B, GSK3A, GSKIP | HTT 2491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.